Free Trial

Krystal Biotech (KRYS) Competitors

Krystal Biotech logo
$301.69 -3.54 (-1.16%)
As of 11:08 AM Eastern
This is a fair market value price provided by Massive. Learn more.

KRYS vs. GMAB, ROIV, UTHR, INCY, and INSM

Should you buy Krystal Biotech stock or one of its competitors? Krystal Biotech's main competitors and comparable companies include Genmab A/S (GMAB), Roivant Sciences (ROIV), United Therapeutics (UTHR), Incyte (INCY), and Insmed (INSM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Krystal Biotech compare to Genmab A/S?

Krystal Biotech (NASDAQ:KRYS) and Genmab A/S (NASDAQ:GMAB) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Krystal Biotech has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

Genmab A/S has higher revenue and earnings than Krystal Biotech. Krystal Biotech is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Krystal Biotech$389.13M23.24$204.83M$7.3741.42
Genmab A/S$3.72B8.62$963M$1.1743.91

In the previous week, Genmab A/S had 16 more articles in the media than Krystal Biotech. MarketBeat recorded 19 mentions for Genmab A/S and 3 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.89 beat Genmab A/S's score of -0.15 indicating that Krystal Biotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Krystal Biotech
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Genmab A/S
3 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Krystal Biotech has a net margin of 47.91% compared to Genmab A/S's net margin of 16.97%. Krystal Biotech's return on equity of 17.02% beat Genmab A/S's return on equity.

Company Net Margins Return on Equity Return on Assets
Krystal Biotech47.91% 17.02% 15.48%
Genmab A/S 16.97%13.67%6.42%

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Krystal Biotech currently has a consensus target price of $375.00, suggesting a potential upside of 22.86%. Genmab A/S has a consensus target price of $53.50, suggesting a potential upside of 4.15%. Given Krystal Biotech's higher possible upside, equities research analysts plainly believe Krystal Biotech is more favorable than Genmab A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Krystal Biotech
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
2.93
Genmab A/S
0 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
3.00

Summary

Krystal Biotech beats Genmab A/S on 10 of the 16 factors compared between the two stocks.

How does Krystal Biotech compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Krystal Biotech (NASDAQ:KRYS) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by company insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Roivant Sciences currently has a consensus target price of $46.64, suggesting a potential upside of 17.98%. Krystal Biotech has a consensus target price of $375.00, suggesting a potential upside of 22.86%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Krystal Biotech is more favorable than Roivant Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Roivant Sciences
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.79
Krystal Biotech
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
2.93

Krystal Biotech has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roivant Sciences$8.26M3,467.54-$299.77M-$0.63N/A
Krystal Biotech$389.13M23.24$204.83M$7.3741.42

In the previous week, Roivant Sciences had 24 more articles in the media than Krystal Biotech. MarketBeat recorded 27 mentions for Roivant Sciences and 3 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.89 beat Roivant Sciences' score of 0.50 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Roivant Sciences
7 Very Positive mention(s)
3 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Krystal Biotech
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Krystal Biotech has a net margin of 47.91% compared to Roivant Sciences' net margin of -838.21%. Krystal Biotech's return on equity of 17.02% beat Roivant Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Roivant Sciences-838.21% -22.03% -20.55%
Krystal Biotech 47.91%17.02%15.48%

Roivant Sciences has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

Summary

Krystal Biotech beats Roivant Sciences on 13 of the 16 factors compared between the two stocks.

How does Krystal Biotech compare to United Therapeutics?

Krystal Biotech (NASDAQ:KRYS) and United Therapeutics (NASDAQ:UTHR) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 8.6% of United Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Krystal Biotech has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

In the previous week, United Therapeutics had 26 more articles in the media than Krystal Biotech. MarketBeat recorded 29 mentions for United Therapeutics and 3 mentions for Krystal Biotech. United Therapeutics' average media sentiment score of 0.96 beat Krystal Biotech's score of 0.89 indicating that United Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Krystal Biotech
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
United Therapeutics
13 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Krystal Biotech currently has a consensus price target of $375.00, suggesting a potential upside of 22.86%. United Therapeutics has a consensus price target of $676.40, suggesting a potential upside of 14.42%. Given Krystal Biotech's stronger consensus rating and higher possible upside, research analysts plainly believe Krystal Biotech is more favorable than United Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Krystal Biotech
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
2.93
United Therapeutics
1 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.69

United Therapeutics has higher revenue and earnings than Krystal Biotech. United Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Krystal Biotech$389.13M23.24$204.83M$7.3741.42
United Therapeutics$3.18B7.91$1.33B$26.5022.31

Krystal Biotech has a net margin of 47.91% compared to United Therapeutics' net margin of 38.61%. United Therapeutics' return on equity of 19.18% beat Krystal Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Krystal Biotech47.91% 17.02% 15.48%
United Therapeutics 38.61%19.18%17.07%

Summary

United Therapeutics beats Krystal Biotech on 9 of the 17 factors compared between the two stocks.

How does Krystal Biotech compare to Incyte?

Incyte (NASDAQ:INCY) and Krystal Biotech (NASDAQ:KRYS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

97.0% of Incyte shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 16.2% of Incyte shares are held by insiders. Comparatively, 13.1% of Krystal Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Incyte has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

Incyte has higher revenue and earnings than Krystal Biotech. Krystal Biotech is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Incyte$6.01B4.10$1.29B$1.8864.35
Krystal Biotech$389.13M23.24$204.83M$7.3741.42

In the previous week, Incyte had 15 more articles in the media than Krystal Biotech. MarketBeat recorded 18 mentions for Incyte and 3 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.89 beat Incyte's score of 0.45 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Incyte
8 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
3 Very Negative mention(s)
Neutral
Krystal Biotech
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Krystal Biotech has a net margin of 47.91% compared to Incyte's net margin of 6.71%. Krystal Biotech's return on equity of 17.02% beat Incyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Incyte6.71% 7.92% 6.12%
Krystal Biotech 47.91%17.02%15.48%

Incyte currently has a consensus price target of $132.86, indicating a potential upside of 9.83%. Krystal Biotech has a consensus price target of $375.00, indicating a potential upside of 22.86%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Krystal Biotech is more favorable than Incyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Incyte
0 Sell rating(s)
14 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.44
Krystal Biotech
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
2.93

Summary

Krystal Biotech beats Incyte on 9 of the 17 factors compared between the two stocks.

How does Krystal Biotech compare to Insmed?

Krystal Biotech (NASDAQ:KRYS) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Insmed had 5 more articles in the media than Krystal Biotech. MarketBeat recorded 8 mentions for Insmed and 3 mentions for Krystal Biotech. Insmed's average media sentiment score of 1.17 beat Krystal Biotech's score of 0.89 indicating that Insmed is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Krystal Biotech
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Insmed
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Krystal Biotech has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, Insmed has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market.

Krystal Biotech has a net margin of 47.91% compared to Insmed's net margin of -39.85%. Krystal Biotech's return on equity of 17.02% beat Insmed's return on equity.

Company Net Margins Return on Equity Return on Assets
Krystal Biotech47.91% 17.02% 15.48%
Insmed -39.85%-96.38%-32.55%

Krystal Biotech has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Krystal Biotech$389.13M23.24$204.83M$7.3741.42
Insmed$606.42M43.83-$1.28B-$2.82N/A

86.3% of Krystal Biotech shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by company insiders. Comparatively, 2.1% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Krystal Biotech currently has a consensus target price of $375.00, indicating a potential upside of 22.86%. Insmed has a consensus target price of $196.52, indicating a potential upside of 62.20%. Given Insmed's higher possible upside, analysts plainly believe Insmed is more favorable than Krystal Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Krystal Biotech
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
2.93
Insmed
1 Sell rating(s)
1 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.92

Summary

Krystal Biotech beats Insmed on 10 of the 17 factors compared between the two stocks.

Get Krystal Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KRYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KRYS vs. The Competition

MetricKrystal BiotechBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$8.94B$4.13B$7.91B$11.87B
Dividend YieldN/A3.64%2.47%4.41%
P/E Ratio40.9324.5933.4030.01
Price / Sales22.9715.468.225.45
Price / Cash41.8721.8921.0222.32
Price / Book7.174.444.743.89
Net Income$204.83M-$24.19M$3.52B$391.27M
7 Day Performance-0.45%-5.63%-4.17%-3.54%
1 Month Performance-4.70%-3.24%-2.40%-4.90%
1 Year Performance46.34%-2.92%0.47%-6.86%

Krystal Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KRYS
Krystal Biotech
3.7138 of 5 stars
$301.69
-1.2%
$375.00
+24.3%
+48.1%$8.94B$389.13M40.93295
GMAB
Genmab A/S
2.3049 of 5 stars
$55.80
+4.0%
$53.61
-3.9%
+69.8%$34.40B$3.72B47.693,029
ROIV
Roivant Sciences
2.1045 of 5 stars
$40.67
+4.6%
$46.55
+14.4%
+94.8%$27.61B$8.26MN/A721
UTHR
United Therapeutics
4.6646 of 5 stars
$582.46
+3.6%
$676.40
+16.1%
+26.8%$26.10B$3.18B21.981,400
INCY
Incyte
2.9118 of 5 stars
$121.89
+1.9%
$132.86
+9.0%
+16.1%$25.04B$5.14B64.842,844

Related Companies and Tools


This page (NASDAQ:KRYS) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners